Wellbutrin Research Studies

Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings.
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Evaluating the tolerability of the newer antidepressants.
Major Depression and Heart Disease: Treatment Trials.
Bupropion mimics a transient ischemic attack.
Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism.
Safety profile of sustained-release bupropion in depression: results of three clinical trials.
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs.
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients.
Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression.
Plasma agmatine and platelet imidazoline receptors in depression.
Non-nicotine pharmacotherapy for smoking cessation.
Care of the sexually active depressed patient.
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports.
Bupropion hydrochloride induced serum sickness-like reaction.
Serum sickness induced by bupropion.
Practical considerations for the treatment of depression in elderly and very elderly long-term care patients.
Treatment of depression in patients with heart disease.
Pharmacokinetic considerations of antidepressant use in the elderly.
Lack of effect of cimetidine on the pharmacokinetics of sustained-release bupropion.
Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.
The effect of bupropion on nicotine craving and withdrawal.
Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
Methods to enhance smoking cessation after myocardial infarction.
Helping patients with Crohn's disease quit smoking.
Smoking cessation: nicotine replacement, gums and patches.
A double-blind study comparing idazoxan and bupropion in bipolar depressed patients.
Management of nonresponse and intolerance: switching strategies.
Drug coverage decisions: the role of dollars and values.
Advances in non-nicotine pharmacotherapy for smoking cessation.
Antidepressants upregulate messenger RNA levels of the neuroprotective enzyme superoxide dismutase (SOD1).
Pharmacotherapy of smoking cessation.
Efficacy of sustained-release bupropion in neuropathic pain: an open-label study.
Bupropion-induced isolated impairment of sensory trigeminal nerve function.
Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment.
Bupropion-induced serum sickness-like reaction.
New developments in smoking cessation.
Bupropion: a review of its use in the management of smoking cessation.
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
The treatment of bipolar depression.
Monitoring pregnancy outcomes following prenatal drug exposure through prospective pregnancy registries and passive surveillance: a pharmaceutical company commitment.
Smoking cessation.
Mania with bupropion: a dose-related phenomenon?
The use of bupropion hydrochloride for smoking cessation therapy.
Pathological gambling among cocaine-dependent outpatients.
Pharmacotherapy of nicotine dependence.
Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians.
New treatments for smoking cessation.
Effect of bupropion-SR on orgasmic dysfunction in nondepressed subjects: a pilot study.
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants.
Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs.
Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake inhibitors versus tricyclic antidepressants.
Bupropion is a nicotinic antagonist.
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
[Bupropion combined with nicotine patches in smoking cessation]
Acute hepatitis induced by bupropion.
Effect of dopaminergic drugs on the reserpine-induced lowering of hippocampal theta wave frequency in rats.
Smoking cessation: which aids are worthwhile?
Smoking cessation guidelines for health professionals: an update. Health Education Authority.
[Bupropion: an effective new aid for smoking cessation]
[Successful treatment of depression in a Parkinson disease patient with bupropion]
Bupropion-SR in treatment of social phobia.
Briefing paper--Zyban.
Pharmacologic aids to smoking cessation.
Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder.
Bupropion to aid smoking cessation.
Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects.
COPD. Interventions for smoking cessation and improved ventilatory function.
A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Elevated P-selectin on platelets in depression: response to bupropion.
Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys.
[Antidepressive drug against nicotine. A method for smoking cessation]
Zyban: an effective treatment for nicotine addiction.
A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder.
Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men.
The pharmacology underlying pharmacotherapy for tobacco dependence: a focus on bupropion.
Involvement of dopamine uptake in the discriminative stimulus effects of cocaine.
The role of monoamine uptake in the discriminative stimulus effects of cocaine and related compounds.
The effects of antidepressants on sexual functioning in depressed patients: a review.
Strategies for the treatment of antidepressant-related sexual dysfunction.
Techniques for smoking cessation: what really works?
[Recent advances in research on nicotine dependence and reward mechanism]
[Risk of convulsions due to the use of bupropion as an aid for smoking cessation]
Smoking cessation. Pulling out the stops.
Smoking cessation in the hospitalized patient using the transtheoretical model of behavior change.
Treating nicotine dependence.
Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.
Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression.
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
Effects of bupropion SR on anterior paralimbic function during waking and REM sleep in depression: preliminary findings using.
Tobacco-use cessation programs and policies at the University of Manitoba's faculty of dentistry.
A practical guide to tobacco cessation in dental offices.
Pharmacologic treatments for the nicotine dependent smoker.
Pharmacological aids for smoking cessation.
Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study.
Bupropion overdose in an adolescent.
Bupropion for smoking cessation : predictors of successful outcome.
Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program.
The use of bupropion in the treatment of restlessness after a traumatic brain injury.
Bupropion overdose: a potential problem with the new 'miracle' anti-smoking drug.
Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women.
Bupropion hydrochloride: the development of a chiral separation using an ovomucoid column.
Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.
Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers.
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial.
Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.
Bupropion sustained release for bereavement: results of an open trial.
Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients.
Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man.
Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study.
Bupropion-induced erythema multiforme.
Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.
Bupropion SR worsens mood during marijuana withdrawal in humans.
Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.
Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.
Smoking cessation: integrating recent advances into clinical practice.
Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate.
Tobacco Smoking in Patients with Cardiovascular Disease.
Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender.
Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
[Uneasiness about the safety of bupropion as an aid to smoking cessation unjustified ]
Smoking cessation in cancer prevention.
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior.
The combined use of bupropion, lithium, and venlafaxine during ECT: a case of prolonged seizure activity.
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.
Bitemporal epileptiform discharges induced by bupropion: a case report.
Acute doses of d-amphetamine and bupropion increase cigarette smoking.
[Known methods can reduce tobacco dependence drastically]
A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia.
General Practitioners' views on the provision of nicotine replacement therapy and bupropion.
Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain.
State medicaid coverage for tobacco-dependence treatments--United States, 1998 and 2000.
Pharmacotherapy in smoking cessation.
Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders.
Effect of nonnicotine pharmacotherapy on smoking behavior.
New medications for nicotine dependence treatment.
Combined behavioral and pharmacological treatments for smoking cessation.
Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report.
Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.
Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.
Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?
Amfebutamone/bupropion for smoking cessation: new preparation. Nicotine replacement therapy is safer.
Tobacco addiction and pharmacological interventions.
Bupropion-induced acute dystonia.
Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence.
Treatment of nicotine addiction.
Using nicotine replacement therapy in treating nicotine addiction in adolescents.
Smoking cessation: the role of bupropion among new pharmacologic agents.
Bupropion-sustained release as a treatment for SSRI-induced sexual side effects.
Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder.
[Treatment of nicotine addiction. Drug therapy for smoking cessation]
Smoking cessation: integration of behavioral and drug therapies.
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Bupropion (Zyban) toxicity.
Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department.
Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapies.
Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex.
Pharmacological management of smoking cessation.
Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression.
Effects of gender on relapse prevention in smokers treated with bupropion SR.
Sustained-release bupropion overdose: a new entity for Australian emergency departments.
Bupropion for amphetamine withdrawal syndrome.
Serving underserved and hard-core smokers in a dental school setting.
The effect of bupropion sustained-release on cigarette craving after smoking cessation.
Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.
Nicotine dependence: the role for antidepressants and anxiolytics.
Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
Nicotine-like discriminative stimulus effects of bupropion in rats.
Bupropion sustained release. A therapeutic review of Zyban.
Nicotine and bupropion share a similar discriminative stimulus effect.
Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment.
The pharmacotherapy of smoking cessation.
Dr Bupropion and Mr Amfebutamone.
Generalized pustular and erythrodermic psoriasis associated with bupropion treatment.
A placebo controlled trial of bupropion for smoking cessation in schizophrenia.
Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.
Mediating mechanisms for the impact of bupropion in smoking cessation treatment.
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
Pharmacokinetic optimisation of sustained-release bupropion for smoking cessation.
Clinical efficacy of bupropion in the management of smoking cessation.
Use of sustained-release bupropion in specific patient populations for smoking cessation.
Tolerability and safety of sustained-release bupropion in the management of smoking cessation.
Current approaches to the management of smoking cessation.
Pharmacoeconomic considerations in the management of smoking cessation.
Participation of African Americans in a smoking cessation trial: a quantitative and qualitative study.
Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial.
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.
Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine.
Bupropion occupancy of the dopamine transporter is low during clinical treatment.
Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome.
[Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy]
A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation.
Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study.
Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy?
Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study.
Adverse drug reaction update.
Psychological intervention and antidepressant treatment in smoking cessation.
Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
Managing nicotine addiction.
Effectiveness of tobacco counseling in the dental office.
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Cardiotoxicity following bupropion overdose.
Imidazoline receptors: possible involvement in the pathophysiology and treatment of depression.
Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Serum bupropion levels in 2 breastfeeding mother-infant pairs.
Risk factors for falls during treatment of late-life depression.
The impact of bupropion on psychomotor performance.
Pharmacogenetic investigation of smoking cessation treatment.
Does insurance coverage for drug therapy affect smoking cessation?
Clinical effectiveness of sustained-release bupropion and behavior therapy for tobacco dependence in a clinical setting.
Investigating the actions of bupropion on dependence-related effects of nicotine in rats.
First-line pharmacotherapy for tobacco use and dependence.
Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion.
Effect of bupropion-SR on REM sleep: relationship to antidepressant response.
Direct evidence of facilitative actions of dopamine in the medial preoptic area on reflexive and noncontact erections in male rats.
Adverse drug reaction update.
A Treatment Algorithm for Attention Deficit Hyperactivity Disorder in Cocaine-Dependent Adults: A One-Year Private Practice Study with Long-Acting Stimulants, Fluoxetine, and Bupropion.
[Bupropion: risks and advantages of its use. What preclinical research says]
Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.
[Bupropion as an aid for smoking cessation]
Bupropion poisoning: a case series.
Nortriptyline effective for smoking cessation.
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.
Acute liver failure with concurrent bupropion and carbimazole therapy.
Novel treatments for attention-deficit/hyperactivity disorder in children.
Endogenous and exogenous dopamine presynaptically inhibits glutamatergic reticulospinal transmission via an action of D2-receptors on N-type Ca2+ channels.
A retrospective survey of the use of bupropion slow release by members of the Canadian Armed Forces.
Naturalistic, self-assignment comparative trial of bupropion SR, a nicotine patch, or both for smoking cessation treatment in primary care.
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration.
Reproductive life events and sexual functioning in women: case reports.
Blinding controlled-release tablets for clinical trials.
Bupropion: pharmacological and clinical profile in smoking cessation.
[Smoking cessation in coronary patients]
Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.
A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients.
Cardiotoxicity associated with intentional ziprasidone and bupropion overdose.
Smoking withdrawal dynamics: II. Improved tests of withdrawal-relapse relations.
Bupropion SR for smoking cessation.
Sleepiness and Unintended Sleep in Parkinson's Disease.
Non-stimulant treatment of attention-deficit/hyperactivity disorder.
Evidence for the involvement of dopamine in ambulation promoted by menthol in mice.
Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.
Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting.
Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat.
Twenty-first century tobacco use: it is not just a risk factor anymore.
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
Catecholamine release in human heart by bupropion.
Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.
Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience.
Cardiotoxicity associated with intentional ziprasidone and bupropion overdose.
Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile.
Targeting smokers at increased risk for relapse: treating women and those with a history of depression.
Seizure associated with sleep deprivation and sustained-release bupropion.
Treatments for spit tobacco use: a quantitative systematic review.
Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
Drug-induced rash with eosinophilia and systemic symptoms syndrome with bupropion administration.
Combination pharmacotherapy in children and adolescents with bipolar disorder.
Effect of bupropion on nicotine self-administration in rats.
Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse.
Neurochemical and psychotropic effects of bupropion in healthy male subjects.
Ephedrine and other stimulants as ergogenic aids.
Switching to bupropion in fluoxetine-resistant major depressive disorder.
Bupropion overdose: QTc prolongation and its clinical significance.
An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder.
Pharmacotherapies to enhance smoking cessation during pregnancy.
Review of bupropion for smoking cessation.
A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation.
Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.
The role of pharmacotherapy in assisting smoking cessation.
Antidepressant-like effects in various mice strains in the tail suspension test.
Zyban-- is there a cause for concern?
Behavioral and biochemical investigations of bupropion metabolites.
Bupropion sustained release for treatment of tobacco dependence.
Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion.
Influence of complex solubility on formulations based on lambda carrageenan and basic drugs.
Tissue distribution of bupropion in a fatal overdose.
Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies.
Chest pain during use of bupropion as an aid in smoking cessation.
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
HPLC determination and pharmacokinetics of sustained-release bupropion tablets in dogs.
[Duration of antidepressive treatments]
Bupropion-induced somnambulism.
Effects of bupropion on core body temperature of mice.
Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum.
A case of monthly unipolar psychotic depression with suicide attempt by self-burning: selective response to bupropion treatment.
Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach.
The use of antidepressants to treat attention deficit hyperactivity disorder in adults.
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Does menthol attenuate the effect of bupropion among African American smokers?
Bupropion and alcohol fatal intoxication: case report.
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation.
In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography.
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression.
Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial.
Determinants for successful smoking cessation with bupropion in daily practice.
[Smoking cessation program based on pharmacological support (bupropion SR). Our own experience]
The place of pharmacotherapy products in smoking cessation.
Smoking withdrawal dynamics: III. Correlates of withdrawal heterogeneity.
[Economic evaluation of pharmacotherapies for smoking cessation]
Open trial of bupropion SR in adolescent major depression.
Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.
Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
Stopping smoking can cause constipation.
Controlled trial for smoking cessation in a Navy shipboard population using nicotine patch, sustained-release buproprion, or both.
Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose.
Predictive factors in smoking cessation with combined therapy with bupropion and nicotine patches.
The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats.
Smoking cessation.
Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.
Suicide in pregnancy.
Predicting adoption of home smoking restriction by inner-city black smokers.
Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome.
Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?
What can we do in secondary prevention of cigarette smoking?
[New drug therapy of chronic obstructive pulmonary disease]
Amphetamine-like stimulant cessation in an abusing patient treated with bupropion.
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion.
Attention deficit hyperactivity disorder (ADHD)--life insurance implications.
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea.
Improving antidepressant adherence.
Smoking cessation for high school students. Impact evaluation of a novel program.
Current pharmacological treatments for nicotine dependence.
Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study.
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
Analysis of benzene ethylamine derivatives in urine using the programmable dynamic liquid-phase microextraction (LPME) device.
A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.
Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking.
Latinos report less use of pharmaceutical aids when trying to quit smoking.
Heterogeneity in 12-month outcome among female and male smokers.
Bupropion in the treatment of bipolar disorders: the same old story?
Bupropion for Blau syndrome.
Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling.
A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees.
Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use.
The effect of a minimal contact smoking cessation programme in out-patients with chronic obstructive pulmonary disease: a pre-post-test study.
[Bupropion SR for weaning from smoking in relapsed smokers: results of an open multicentre trial in Germany]
Nicotine dependence and psychiatric disorders.
Assessing the effects of bupropion SR on mood dimensions of depression.
Economic rewarding of smoking cessation-facilitating drugs--a comparison of over-the-counter and prescribed nicotine replacement therapy.
National Patterns of Medication Treatment for Depression, 1987 to 2001.
Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment With Bupropion Sustained Release: A Study in Patients With Major Depression.
Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders.
A Trilogy Case Review Highlighting the Clinical and Pharmacologic Applications of Mirtazapine in Reducing Polypharmacy for Anxiety, Agitation, Insomnia, Depression, and Sexual Dysfunction.
Bupropion-Associated Withdrawal Symptoms: A Case Report.
Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion.
Bupropion and paroxetine differentially influence cardiovascular and neuroendocrine responses to stress in depressed patients.
Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective.
Hormonal responses during prolonged exercise are influenced by a selective DA/NA reuptake inhibitor.
[Comprehensive treatment of nicotine dependence in patients with cardiovascular diseases--personal experience]
ADHD treatment across the life cycle.
Impact of ADHD and its treatment on substance abuse in adults.
[Effect of treatment for nicotine dependence in patients with COPD]
Hidden amphetamines: from smoking cessation to diabetes.
Tobacco cessation and nicotine replacement therapy for dental practice.
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Bupropion sustained release treatment reduces fatigue in cancer patients.
High-throughput liquid chromatography-tandem mass spectrometry determination of bupropion and its metabolites in human, mouse and rat plasma using a monolithic column.
Combination of bupropion, paroxetine and quetiapine as adjuvant treatment for multiple myeloma.
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Smoking cessation and weight gain.
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction.
Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression.
Early- and late-onset startle modulation in unipolar depression.
Does bupropion have advantages over other medical therapies in the cessation of smoking?
Bupropion in the management of apathy.
Effects of sibutramine on the central dopaminergic system in rodents.
Bupropion as an aid to smoking cessation: a review of real-life effectiveness.
Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women.
Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response.
[Treatment of tobacco dependence: brief and intensive clinical intervention]
Bupropion sustained release for panic disorder.
Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study.
Changes in food reward following smoking cessation: a pharmacogenetic investigation.
Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies?
Bupropion for treatment of interferon-induced depression.
SSRI treatment-associated stroke: causality assessment in two cases.
Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Validated assays for human cytochrome P450 activities.
Does a health plan effort to increase smokers' awareness of cessation medication coverage increase utilization and cessation?
Pharmacological management of attention-deficit hyperactivity disorder.
Residential treatment for smokeless tobacco use: a case series.
Do small lapses predict relapse to smoking behavior under bupropion treatment?
Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers.
Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care.
Reducing risk in smokers.
Somatic therapy for major depressive disorder: selection of an antidepressant.
Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.
[Bupropion-induced epileptic seizures]
Psychiatric morbidity in psoriasis: a review.
Bupropion (Zyban, Wellbutrin) inhibits nicotine-induced viral reactivation in herpes simplex virus type 1 latent rabbits.
Assessing harmful effects in systematic reviews.
Intentional bupropion overdoses.
Do smokers know how to quit? Knowledge and perceived effectiveness of cessation assistance as predictors of cessation behaviour.
Interventions for smokeless tobacco use cessation.
Bupropion effects on aggressiveness and anxiety in OF1 male mice.
Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers.
Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
A case of prolonged seizure activity after combined use of bupropion and clomipramine.
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors.
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats.
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor.
Blood levels and acute response to bupropion.
Convulsant and anticonvulsant effects of bupropion in mice.
Pharmacological characterisation of the thermogenic effect of bupropion.
Bupropion for smoking cessation: a randomized trial.
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective.
Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol.
Tobacco cessation pharmacotherapy use among First Nations persons residing within British Columbia.
Rhabdomyolysis connected with the use of bupropion.
Organic mental disorders associated with bupropion in three patients.
Pharmacotherapy of tobacco dependence.
Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial.
Bupropion SR for relapse prevention: a "slips-allowed" analysis.
Depressed smokers and stage of change: implications for treatment interventions.
Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.
Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR.
GP prescribing of nicotine replacement and bupropion to aid smoking cessation in England and Wales.
Zyban for smoking cessation in a general practice setting: the response to an invitation to make a quit attempt.
Efficacy of noradrenergic-selective agents in the treatment of neuropsychiatric diseases.
[Methods and cost effectiveness of nicotine abstinence]
Bupropion may support psychosocial treatment of nicotine-dependent adolescents: preliminary results.
Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test.
[Continuous and momentous tobacco abstinence with pharmacologic therapy in clinical practice]
[Acute psychosis after administration of bupropion hydrochloride (Zyban)]
Daytime sleepiness and insomnia as correlates of depression.
Therapeutic drug monitoring of non-tricyclic antidepressant drugs.
Joint symptoms in patients on bupropion therapy.
Effect of bupropion on nocturnal urinary free cortisol and its association with antidepressant response.
Serotonin syndrome induced by a combination of bupropion and SSRIs.
Quitline in smoking cessation: a cost-effectiveness analysis.
Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice.
Acute psychosis following sustained release bupropion overdose.
The nurse's role in promoting smoking cessation.
Pharmacist-managed tobacco cessation program in Veterans Health Administration community-based outpatient clinic.
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion.
Pediatric bupropion-induced serum sicknesslike reaction.
Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
[Current therapeutic strategies in smoking cessation]
Efficacy of bupropion in the indigenous Maori population in New Zealand.
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.
Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression.
Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study.
Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.
Effects of acute bupropion administration on locomotor activity in adolescent and adult mice.
Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort.
National trends in the provision of smoking cessation aids within the Veterans Health Administration.
Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.
[ABC of smoking cessation. Bupropion and other drugs in non-nicotine therapy]
General practitioners' views on and referral to NHS smoking cessation services.
Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies.
Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study.
[Treatment of nicotine dependence based on bupropion SR and educational support--one year observation and analysis of the reasons of relapses]
[Veracity of smokers' reports of abstinence at smoking cessation clinics]
Outcomes from an outpatient smoking-cessation clinic.
The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects.
Steady-state pharmacokinetics of bupropion SR in juvenile patients.
Effectiveness of bupropion for smoking cessation during pregnancy.
[Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)]
[Safety of Zyban administration in nicotine dependence treatment]
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Frequency of physician-directed assistance for smoking cessation in patients receiving cessation medications.
The impact of smoking cessation on objective and subjective markers of sleep: review, synthesis, and recommendations.
Recent quitters' interest in recycling and harm reduction.
Review article: smoking cessation as primary therapy to modify the course of Crohn's disease.
Bupropion SR for the treatment of postpartum depression: a pilot study.
Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study.
Smoking cessation: what works in primary care settings.
[Review of antidepressants from the TCAs to the third generation drugs]
Using metaanalysis to evaluate evidence: practical tips and traps.
Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions.
Clinical inquiries. What interventions can help patients stop using chewing tobacco?
The pharmacotherapy of panic disorder.
Awareness and use of smoking cessation treatments among diabetic patients.
The participation of health professionals in a smoking-cessation programme positively influences the smoking cessation advice given to patients.
Treatment Enhances Ultradian Rhythms of CSF Monoamine Metabolites in Patients with Major Depressive Episodes.
Is antagonism of alpha3beta4 nicotinic receptors a strategy to reduce morphine dependence?
Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs.
Non-nicotine pharmacotherapies for nicotine dependence.
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia.
Inhibition of CYP2D6 activity by bupropion.
Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
[COPD-rehabilitation]
Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat.
Why isn't bupropion the most frequently prescribed antidepressant?
Effects of monoamine reuptake inhibitors on wet-dog shakes mediated by 5-HT2A receptors in ACTH-treated rats.
Bupropion SR vs placebo for smoking cessation in health care professionals.
Exposure measures applied to the bioequivalence of two sustained release formulations of bupropion.
Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.
Atomoxetine use associated with onset of a motor tic.
Acute dopamine/norepinephrine reuptake inhibition increases brain and core temperature in rats.
Proposal for using small molecule tumor necrosis factor-alpha lowering agents, possibly bupropion, in aplastic anemia.
Impact of UK policy initiatives on use of medicines to aid smoking cessation.
Body image treatment for weight concerned smokers: a pilot study.
Falling backward in two elderly patients taking bupropion.
Anti-apoptosis function of TNF-alpha in chronic lymphocytic leukemia: lessons from Crohn's disease and the therapeutic potential of bupropion to lower TNF-alpha.
Tobacco cessation in primary care: maximizing intervention strategies.
PHARMAC and tobacco control in New Zealand: government policy 'up in smoke'.
Psychopathology in neuropsychiatry: DSM and beyond.
Does pretreatment insomnia or anxiety predict acute response to bupropion SR?
Medication compliance during a smoking cessation clinical trial: a brief intervention using MEMS feedback.
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Role of dopamine in behavioral sensitization to ethanol in DBA/2J mice.
Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: New insights into the biology of TNF-alpha giving new treatment opportunities-the role of bupropion.
Conversion from sustained-release to immediate-release bupropion: patient tolerability and economic impact.
Pharmacotherapy for obesity.
Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines.
Smoking cessation in patients with coronary artery disease.
Oxygen as a therapy for reducing nicotine withdrawal symptoms.
Monoamine oxidase inhibitors and atypical antidepressants.
Antidepressants and periodic leg movements of sleep.
Bupropion increases striatal vesicular monoamine transport.
Non-nicotine pharmacotherapies for smoking cessation.
HPLC assay for bupropion and its major metabolites in human plasma.
A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.
Pharmacogenetics and nicotine addiction treatment.
Treating depression in a mother of five: what to do when the first step fails.
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL.
North American Association for the Study of Obesity annual meeting.
Offering telephone counseling to smokers using pharmacotherapy.
Acceptance of nicotine dependence treatment among currently depressed smokers.
Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion.
An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners.
The management of fatigue in depressed patients.
What to do with a patient who smokes.
Smoking cessation treatment in primary care: prospective cohort study.
Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats.
A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test.
Stress and Quitting Among African American Smokers.
The Effects of Chronic Norepinephrine Transporter Inactivation on Seizure Susceptibility in Mice.
Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network.
Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
Pharmacotherapy and pharmacogenetics of nicotine dependence.
A dynamic population model of disease progression in COPD.
Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
Cocaine alters catalase activity in prefrontal cortex and striatum of mice.
Adverse effects of pharmacological therapy for nicotine addiction in smokers following a smoking cessation program.
Nortriptyline for smoking cessation: A review.
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests.
Antidepressant drug induced alterations in binding to central dopamine transporter sites in the Wistar Kyoto rat strain.
Effects of biochemically confirmed smoking cessation on white blood cell count.
Treatment of methadone-maintained patients with adult ADHD: Double-blind comparison of methylphenidate, bupropion and placebo.
Bupropion: seizures in an infant exposed through breast-feeding.
How does bupropion work as a smoking cessation aid?
Drug therapy for smoking cessation: evidence-based considerations for dentistry.
Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials.
Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.
The prevalence of weight concerns in a smoking abstinence clinical trial.
Smoking status of Australian general practice patients and their attempts to quit.
A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine.
Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h.
Strategies for managing antidepressant-induced sexual dysfunction: Systematic review of randomised controlled trials.
Bupropion attenuates nicotine abstinence syndrome in the rat.
Medication screening for smoking cessation: a proposal for new methodologies.
Safety of intravenous methamphetamine administration during treatment with bupropion.
Use of Bupropion in Combination with Serotonin Reuptake Inhibitors.
Pharmacotherapy for nicotine dependence.
Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency.
Intraventricular conduction delay after bupropion overdose.
Adverse effects associated with extra doses of bupropion.
Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia.
Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin.
A randomized, open-label pilot comparison of gabapentin and bupropion SR for smoking cessation.
Bupropion-induced subacute cutaneous lupus erythematosus.
A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain.
The efficacy of bupropion in winter depression: results of an open trial.
Different effects of direct and indirect dopamine receptor agonists on immobility time in reserpine-treated mice.
A 102-center prospective study of seizure in association with bupropion.
Imipramine as a discriminative stimulus.
Mass spectrometric investigation of 2-aminopropiophenones and some of their metabolites.
Pharmacokinetics of second generation antidepressants: bupropion.
Should bupropion dosage be adjusted based upon therapeutic drug monitoring?
Comparative analysis of the effects of iontophoretically applied dopamine in different regions of the rat brain, with special reference to the cingulate cortex.
Speed of onset of action of the newer antidepressants--fluoxetine and bupropion.
Treatment of depression. New pharmacologic approaches.
Menstrual irregularities associated with bupropion treatment.
Bupropion: overview and prescribing guidelines in depression.
Cardiovascular effects of bupropion in depressed patients with heart disease.
Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study.
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists.
Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection.
[GABAergic modulation of amnesic trace reproduction by activation of the dopaminergic system]
Phenytoin-bupropion interaction: effect on plasma phenytoin concentration in the rat.
A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development.
Bupropion: new therapy for depression.
A case of bupropion-associated delirium.
Bupropion treatment of attention-deficit hyperactivity disorder in adults.
Antidepressants, metabolites, and apparent drug resistance.
Antidepressant profile of bupropion and three metabolites in mice.
Substitution of psychoactive drugs in pentobarbital-dependent rats.
Bupropion as a promising approach to rapid cycling bipolar II patients.
Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease.
Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat.
Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine.
Pharmacological responsiveness of winter depression.
Effects on opioid-induced rate reductions by doxepin and bupropion.
[Specifics of participation of dopaminergic and serotoninergic systems of the brain in latent inhibition based on pharmacological models]
Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis.
Effect of bupropion on cimetidine and ranitidine absorption in rats.
Seizures and bupropion: a review.
Strain-specific effects of antidepressants on escape deficits induced by inescapable shock.
Lack of effect of the antidepressant compound bupropion on pineal indoleamines.
Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys.
Dissociation of the actions of uptake blockers upon dopamine overflow and uptake in the rat nucleus accumbens: in vivo voltammetric data.
A case of mania secondary to propafenone.
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
Characterization of the bupropion cue in the rat: lack of evidence for a dopaminergic mechanism.
Antidepressant drug therapy in the elderly: enhancing safety and compliance.
Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.
Amphetamine-like effects of anorectics and related compounds in pigeons.
Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys.
The effect of H2-antagonists on the absorption of bupropion in rats.
Behavioral effects of histamine H1 antagonists: comparison with other drugs and modification by haloperidol.
Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry.
The new generation antidepressants: promising innovations or disappointments?
Down regulation of beta-receptors by bupropion and its major metabolite in mouse brain.
Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
Forms of atypical depression and their response to antidepressant drugs.
Brain regional [3H]flunitrazepam binding in rats chronically treated with bupropion or B.W.306U.
Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine.
Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons.
Adverse reactions to five new antidepressants.
Antidepressant drug therapy for bulimia: current status.
Design and synthesis of a hapten for the radioimmunoassay of bupropion.
Lithium and bupropion antagonise the phasic changes in locomotor activity caused by dopamine infused into the rat nucleus accumbens.
A case of bupropion-induced seizure.
Striatal dopamine uptake and swim performance of the aged rat.
The effect of experimentally-induced renal failure on accumulation of bupropion and its major basic metabolites in plasma and brain of guinea pigs.
Bupropion effects in attention deficit and conduct disorders.
Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
Antagonism of the behavioral effects of cocaine and d-amphetamine by prazosin.
Bupropion. Effects on cerebral monoamines in rat and on blood pressure in dog.
Pharmacological significance of the species differences in bupropion metabolism.
Control of prolactin release induced by suckling.
Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure.
Pharmacologic modification of psychosexual dysfunction.
Bupropion in depression. I. Biochemical effects and clinical response.
Bupropion in depression. II. The role of metabolites in clinical outcome.
Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output.
Anorectic and behavioural effects of bupropion.
[Bupropion activation of memory trace retrieval in amnesia and forgetting]
Treatment of bulimia with bupropion: a multicenter controlled trial.
Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study.
Effect of hepatic and renal dysfunction on disposition of bupropion in rats.
Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.
Bupropion--an antidepressant without sexual pathophysiological action.
Rapid improvement of delusional depression following drug-induced seizures: case report.
Efficacy of lithium-tranylcypromine treatment in refractory depression.
Alcohol interactions with typical and atypical antidepressants.
Antidepressant drug therapy: the role of the new antidepressants.
Activity of dopamine-containing substantia nigra neurons in freely moving cats.
Alternative therapies for bipolar disorder.
Behavioral and eegraphic changes induced by dopaminergic antidepressants in rabbits.
Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose.
The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.
Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum.
The conditioned place preference paradigm in rats: effect of bupropion.
Central effects of repeated treatment with bupropion.
Psychoses associated with bupropion treatment.
Stress-induced neurological impairments in an animal model of parkinsonism.
Stability of bupropion and its major metabolites in human plasma.
Acute effects of antidepressants on hippocampal seizures.
Differential effects of d-amphetamine, pipradrol and bupropion on shuttlebox self-stimulation.
The lack of effect of bupropion HCL (Wellbatrin) on the secretion of growth hormone and prolactin in humans.
Review of bupropion.
Effect of bupropion on dopamine and 5-hydroxytryptamine-mediated behaviour in mice.
Second-generation antidepressants.
Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion . HCl--a new atypical antidepressant agent.
Daily bupropion injections for 3 weeks attenuate the NE stimulation of adenylate cyclase and the number of beta-adrenergic recognition sites in rat frontal cortex.
Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain.
Radioimmunoassay for bupropion in human plasma: comparison of tritiated and iodinated radioligands.
Effects of bupropion, nomifensine and dexamphetamine on performance, subjective feelings, autonomic variables and electroencephalogram in healthy volunteers.
Evaluation of the safety and efficacy of bupropion in depression.
Review of placebo-controlled trials with bupropion.
A double-blind comparison of bupropion and amitriptyline in depressed inpatients.
A comparative study of bupropion and amitriptyline in depressed outpatients.
Bupropion and amitriptyline in the treatment of depressed patients.
Clinical pharmacology of bupropion and imipramine in elderly depressives.
Safety and efficacy of bupropion in elderly patients: preliminary observations.
Antidepressant response and plasma concentrations of bupropion.
Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients.
Efficacy of bupropion in tricyclic-resistant or intolerant patients.
Long-term efficacy and safety of bupropion.
Long-term preventive care in depression: the use of bupropion in patients intolerant of other antidepressants.
Bupropion's prophylactic efficacy in bipolar affective illness.
Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants.
Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients.
The cardiovascular profile of bupropion.
Effects of bupropion on body weight.
Methodologic approach to adverse events applied to bupropion clinical trials.
Overview of clinically significant adverse reactions to bupropion.
Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion.
Psychopharmacology of bupropion in normal volunteers.
Bupropion: clinical assay for amphetamine-like abuse potential.
Failure of bupropion to affect prolactin or growth hormone in man.
The chemistry of bupropion.
Preclinical toxicology of bupropion: an overview.
Animal models used in prediction of antidepressant effects in man.
The pharmacologic basis for therapeutic interest in bupropion.
Studies of bupropion's mechanism of antidepressant activity.
Metabolism and kinetics of bupropion.
Clinical pharmacokinetics of bupropion: a review.
The use of bupropion in hospitalized depressed patients.
A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients.
Bupropion in depression: a tri-center placebo-controlled study.
Bupropion, d-amphetamine, and amitriptyline-induced conditioned taste aversion in rats: dose effects.
Comparative efficacy and safety of bupropion and placebo in the treatment of depression.
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers.
Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants.
A double-blind study of bupropion and placebo in depression.
Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats.
Bupropion in the treatment of psychotic depression: two case reports.
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification.
Imipramine-induced inappropriate ADH secretion.
Bupropion in Parkinson's disease.
Alcohol and bupropion pharmacokinetics in healthy male volunteers.
The effect of bupropion, a new antidepressant drug, and alcohol and their interaction in man.
Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations.
Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection.
Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment.
Bupropion hydrochloride.
Determination of plasma bupropion and its relationship to therapeutic effect.
Evaluating drug effects on children's cognitive functioning.
Stimulus properties of antidepressants in the rat.
Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo.
Radioimmunoassay and pharmacokinetic profile of bupropion in the dog.
Drug alterations of punished responding after chlordiazepoxide: possible screen for agents useful in minimal brain dysfunction.
Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.
Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds.
Perceptual changes with bupropion, a novel antidepressant.
Effects of dopamine uptake inhibitors on schedule-controlled behavior in the squirrel monkey.
A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients.
Rate of binding of various inhibitors at the dopamine transporter in vivo.
Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder.
Bupropion/nortriptyline combination for refractory depression.
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Bupropion: a review of its mechanism of antidepressant activity.
Assessment of the discriminative stimulus effects of cocaine in the rat: lack of interaction with opioids.
A high-performance liquid chromatographic method for quantitating bupropion in human plasma or serum.
Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.
Prescribing trends of antidepressants in bipolar depression.
The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.
Dopamine transporter mediated release of dopamine: role of chloride.
REM sleep enhancement by bupropion in depressed men.
Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism.
Treating anxiety in patients with alcoholism.
Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder.
A double-blind trial of bupropion versus desipramine for bipolar depression.
Antidepressant-associated mania: a controlled comparison with spontaneous mania.
Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report.
Geriatric depression: brain imaging correlates and pharmacologic considerations.
Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies.
Trazodone for antidepressant-associated insomnia.
Comparison of bupropion and trazodone for the treatment of major depression.
Dysthymic and cyclothymic depressions: therapeutic considerations.
Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants.
Comparative tolerability profiles of the newer versus older antidepressants.
Bupropion overdose and seizure.
Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion.
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Bupropion overdose: a 3-year multi-center retrospective analysis.
Changes concurrent with initiation of abstinence from cocaine abuse.
Three fatal drug overdoses involving bupropion.
Bupropion and secondary mania. Is there a relationship?
Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures.
Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome.
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.
Review of the cardiovascular effects of heterocyclic antidepressants.
Pharmacologic treatment of depression in the elderly.
Excretion of bupropion in breast milk.
Eosinophilia associated with bupropion.
Bupropion and anticonvulsant drug interactions.
New approaches to the treatment of depression.
The diagnosis and treatment of late-life depression.
A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients.
Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression.
Carbamazepine but not valproate induces bupropion metabolism.
Different effects of the antidepressant drugs imipramine, maprotiline and bupropion on insulin secretion from mouse pancreatic islets.
New antidepressant drugs and the treatment of depression in the medically ill patient.
Sexual side effects of antidepressants: a review.
Bupropion plasma levels and CYP2D6 phenotype.
Bupropion hydrochloride in attention deficit disorder with hyperactivity.
New antidepressants: more options for tailoring treatment.
Bupropion induces sniffing: a possible dopaminergic mechanism.
Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls.
Functional status in depressed patients: the relationship to disease severity and disease resolution.
Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine.
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
Fatal bupropion overdose.
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
The effects of bupropion in vivo in the neostriatum of 5-day-old and adult rats.
Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography.
Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
Bupropion and sexual function: a placebo-controlled prospective study on diabetic men with erectile dysfunction.
A comparison of sustained-release bupropion and placebo for smoking cessation.
Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers.
Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats.
Issues in the treatment of women with bipolar illness.
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.
Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction.
Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test.
Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.
Bupropion sustained release: a therapeutic overview.
Bupropion sustained release: side effect profile.
Antidepressant-induced sexual dysfunction.
Depression, sleep, and antidepressants.
Bupropion sustained release and smoking cessation.
The Expert Consensus Guidelines for treating depression in bipolar disorder.
Diagnosis and treatment of depression in late life.
ADHD through the life span: the role of bupropion in treatment.
Treatment of depression in elderly patients: recent advances.
Conformational analysis and a crystal structure of bupropion, an antidepressant with dopamine reuptake blocking activity.
Use of bupropion with SRIs and venlafaxine.
Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion.
A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings.
Augmentation strategies with serotonergic-noradrenergic combinations.
Smoking cessation: Part 2--Pharmacologic approaches.
A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
Attention-deficit/hyperactivity disorder: a life-span perspective.
Psychopharmacology of ADHD: children and adolescents.
Addressing comorbidity in adults with attention-deficit/hyperactivity disorder.
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain.
ECG conduction delays associated with massive bupropion overdose.
Treatment of antidepressant nonresponders: augmentation or switch?
Bupropion slow-release response in depression: diagnosis and biochemistry.
Bupropion treatment in veterans with posttraumatic stress disorder: an open study.
Psychopharmacologic treatment of acquired attention disorders in children with brain injury.
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder.
Drug therapy to aid in smoking cessation. Tips on maximizing patients' chances for success.
Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.
Recent advances in the pharmacotherapy of smoking.
Melancholia with onset during treatment with SSRIs.